Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MEP1B | Q16820 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17849020 | 0.91 | KMT2A (0.38) | ALDH1A1NPC1GAA | |
| SCHEMBL17849026 | 0.82 | MAPT (0.36) | ALDH1A1MAPTNPC1GAA | |
| SCHEMBL17848983 | 0.82 | MEN1 (0.35) | ALDH1A1AKR1C3AKR1C2MAPTNPC1 | |
| Methyl Alcohol SCHEMBL17848974 | 0.81 | MEN1 (0.35) | ALDH1A1AKR1C3AKR1C2MAPTNPC1 | |
| SCHEMBL17848962 | 0.81 | ALDH1A1 (0.41) | ALDH1A1MAPTNPC1 | |
| SCHEMBL17848988 | 0.80 | KMT2A (0.46) | ALDH1A1GAA | |
| SCHEMBL1170580 | 0.77 | CTSL (0.49) | ALDH1A1MAPTGAA | |
| SCHEMBL18586090 | 0.64 | ALDH1A1 (0.39) | ALDH1A1MAPT | |
| SCHEMBL11313050 | 0.62 | ALDH1A1 (0.48) | ALDH1A1 | |
| SCHEMBL2500845 | 0.62 | MYC (0.61) | ALDH1A1MAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233886-B1 | COMPOUNDS IN THE FAMILY OF N-ACYLAMINO-AMIDES, COMPOSITIONS COMPRISING THEM, AND USES | OREAL (FR) | 2020-02-26 | — | — | EP | disclosed |
| US-20170360667-A1 | NEW COMPOUNDS IN THE FAMILY OF N-ACYLAMINO-AMIDES, COMPOSITIONS COMPRISING THEM, AND USES | L'OREAL (FR) | 2017-12-21 | — | — | US | disclosed |
| EP-3233886-A1 | COMPOUNDS IN THE FAMILY OF N-ACYLAMINO-AMIDES, COMPOSITIONS COMPRISING THEM, AND USES | L'Oréal (FR) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016096804-A1 | COMPOUNDS IN THE FAMILY OF N-ACYLAMINO-AMIDES, COMPOSITIONS COMPRISING THEM, AND USES | L'OREAL (FR) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360667-A1 | NEW COMPOUNDS IN THE FAMILY OF N-ACYLAMINO-AMIDES, COMPOSITIONS COMPRISING THEM, AND USES | H1-0, CRY1, CCNA1 | ALDH1A1 736/4885AKR1C3 117/4885AKR1C2 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.